by April Breyer Menon | Oct 9, 2026
On October 7, 2026, the Court granted REGENXBIO and Sarepta’s joint stipulations of dismissal of Case Nos. 1:20-cv-01226 (D. Del.) and 1:23-cv-00667 (D. Del.) alleging infringement of The Trustees of the University of Pennsylvania and REGENXBIO’s U.S....
by April Breyer Menon | Oct 4, 2026
On September 25, 2026, the Patent Trial and Appeal Board (“PTAB”) issued Final Written Decisions (“FWD”) in PGR2025-00033 and PGR2025-00039 finding all remaining challenged claims of Halozyme’s U.S. Patent Nos. 12,049,652 (“the ’652 patent”) and 12,104,185 (“the ’185...
by April Breyer Menon | Oct 1, 2026
On September 30, 2026, in Case No. 1:26-cv-00222 (D. Del.), in a sealed opinion, the Court granted Janssen’s motion for a preliminary injunction against the commercial launch of Accord and Bio-Thera’s Simponi® / Simponi Aria® (golimumab) interchangeable...
by April Breyer Menon | Oct 1, 2026
On September 30, 2026, the Federal Circuit denied Eli Lilly’s petition for rehearing en banc of CAFC Appeal No. 24-1094, which reversed the District Court’s grant of judgment as a matter of law that found claims of Teva’s U.S. Patent Nos. 8,546,045, 9,884,907,...
by April Breyer Menon | Sep 28, 2026
On September 24, 2026, the USPTO Director issued a decision explaining the denial of institution of PGR2026-00039, filed by Biocon against Regeneron’s U.S. Patent No. 12,168,036 (“the ’036 patent”). BiologicsHQ previously reported that the Director denied...
